psilocybin has been researched along with Depression in 90 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (4.44) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 21 (23.33) | 24.3611 |
2020's | 65 (72.22) | 2.80 |
Authors | Studies |
---|---|
Chen, WN; Hu, YR; Li, NX; Zhang, B | 1 |
Bourzat, F; Harvey, K; Kryskow, P; Kuypers, KPC; Polito, V; Rootman, JM; Santos-Brault, E; Stamets, P; Walsh, Z | 1 |
Agin-Liebes, G; Davis, AK | 1 |
Breeksema, JJ; Schimmers, N; Schoevers, RA; Smith-Apeldoorn, SY; van den Brink, W; Veraart, J | 1 |
O'Leary, K | 1 |
Fejer, G; Hajkova, K; Kuchar, M; Lempe, P; Marschall, J; Prochazkova, L; van Elk, M | 1 |
Gold, JA; Pearson, C; Siegel, J | 1 |
Jordens, C; Miceli McMillan, R | 1 |
Strous, JFM | 1 |
de la Fuente Revenga, M; Elder, H; González-Maeso, J; Jaster, AM; Marsh, SA; Negus, SS | 1 |
Carhart-Harris, R; Daws, RE; Erritzoe, D; Giribaldi, B; Nutt, D; Roseman, L; Sexton, JD; Timmermann, C; Wall, MB | 1 |
Berens, N; Kim, SY | 1 |
Willyard, C | 1 |
Johannesdottir, A; Sigurdsson, E | 1 |
Eisenstein, M | 1 |
Cleare, AJ; Ko, K; Kopra, EI; Rucker, JJ | 1 |
Dycha, N; Kurzepa, J; Nowak, EM; Psiuk, D; Samardakiewicz, M; Łopuszańska, U | 1 |
Aaronson, ST; Alvarez, O; Arden, PC; Baker, A; Bennett, JC; Bird, C; Blom, RE; Brennan, C; Brusch, D; Burke, L; Campbell-Coker, K; Carhart-Harris, R; Cattell, J; Daniel, A; DeBattista, C; Dunlop, BW; Eisen, K; Feifel, D; Forbes, M; Goodwin, GM; Haumann, HM; Hellerstein, DJ; Hoppe, AI; Husain, MI; Jelen, LA; Kamphuis, J; Kawasaki, J; Kelly, JR; Key, RE; Kishon, R; Knatz Peck, S; Knight, G; Koolen, MHB; Lean, M; Licht, RW; Malievskaia, E; Maples-Keller, JL; Mars, J; Marwood, L; McElhiney, MC; Miller, TL; Mirow, A; Mistry, S; Mletzko-Crowe, T; Modlin, LN; Nielsen, RE; Nielson, EM; O'Keane, V; Offerhaus, SR; Páleníček, T; Printz, D; Rademaker, MC; Reinholdt, F; Repantis, D; Rucker, J; Rudow, S; Ruffell, S; Rush, AJ; Schoevers, RA; Seynaeve, M; Shao, S; Soares, JC; Somers, M; Stansfield, SC; Sterling, D; Strockis, A; Tsai, J; van Reemst, A; Visser, L; Wahba, M; Williams, S; Young, AH; Ywema, P; Zisook, S | 1 |
Madras, BK | 1 |
Carhart-Harris, R; Kaelen, M; Nutt, D; Roseman, L; Shukuroglou, M; Wall, M | 1 |
Barber, G; Nemeroff, CB; Siegel, S | 1 |
Gukasyan, N | 1 |
Aaronson, ST; Alvarez, O; Atli, M; Bennett, JC; Croal, M; DeBattista, C; Dunlop, BW; Feifel, D; Goodwin, GM; Hellerstein, DJ; Husain, MI; Kelly, JR; Lennard-Jones, MR; Licht, RW; Malievskaia, E; Marwood, L; Mistry, S; Páleníček, T; Redjep, O; Repantis, D; Schoevers, RA; Septimus, B; Simmons, HJ; Soares, JC; Somers, M; Stansfield, SC; Stuart, JR; Tadley, HH; Thiara, NK; Tsai, J; Wahba, M; Williams, S; Winzer, RI; Young, AH; Young, MB; Zisook, S | 1 |
Hieronymus, F; Østergaard, SD | 2 |
Benyamina, A; Dervaux, A; Roméo, B | 1 |
Courtet, P; Lengvenyte, A; Olié, E | 1 |
Goodwin, GM; Hellerstein, DJ; Young, AH | 1 |
Rucker, JJ | 1 |
Julia Mertens, L | 1 |
Agrawal, M; Emanuel, E; Richards, B; Richards, W; Roddy, K; Thambi, P | 1 |
Carhart-Harris, RL; Ertl, N; Kaelen, M; Lam, C; Nutt, DJ; Roseman, L; Wall, MB | 1 |
Carhart-Harris, RL; Erritzoe, D; Giribaldi, B; Nutt, DJ; Weiss, B | 1 |
Jha, MK; Kamal, S; Radhakrishnan, R | 1 |
Chakrabarty, T; DuBois, A; Keramatian, K; Saraf, G; Yatham, LN | 1 |
Jawad, MY; Qasim, S; Shad, MU; Zaheer, Z | 1 |
Brown, O | 1 |
Haridy, R | 1 |
D'Souza, DC; Pathania, S; Pittman, B; Safi-Aghdam, H; Skosnik, PD; Sloshower, J; Syed, S | 1 |
Nogrady, B | 1 |
Amit, M; Cohen, L; Ramondetta, LM; Yaniv, D | 1 |
Carhart-Harris, R; Carlbring, P; Davis, AK; Erritzoe, D; Goldberg, SB; Griffiths, RR; Nutt, DJ; Simonsson, O | 1 |
De Pieri, M; Kaiser, S; Kirschner, M; Langlest, F; Mallet, L; Perez, N; Sabé, M; Sentissi, O; Seragnoli, F; Solmi, M; Thorens, G; Zullino, D | 1 |
Carlyle, D; Crowe, M; Lacey, C; Manuel, J | 1 |
Müller, T | 1 |
Chen-Li, DCJ; Fancy, F; Haikazian, S; Husain, MI; Johnson, DE; Levinta, A; Mansur, RB; McIntyre, RS; Rosenblat, JD | 1 |
Reardon, S | 1 |
Chruścicka-Smaga, B; Machaczka, A; Pilc, A; Szewczyk, B | 1 |
Boudreau, E; Orlowski, K | 1 |
Ahmed, H; Arshad, T; Mushahid, H | 1 |
Germann, CB | 1 |
Amada, N; Jungaberle, H; Klein, M; Lea, T; Schecke, H | 1 |
Goldberg, SB; Hutson, PR; Nicholas, CR; Pace, BT; Raison, CL | 1 |
Jones, TK; Lippmann, S | 1 |
Mathuru, AS; Vitkauskas, M | 1 |
Reynolds, CF | 1 |
de Manincor, M; Galvão-Coelho, NL; Gonzalez, M; Marx, W; Perkins, D; Sarris, J; Sinclair, J | 1 |
Tullis, P | 1 |
Bouso, JC; Dos Santos, RG; Hallak, JEC; Ona, G | 1 |
Cole, AB; Hesselgrave, N; Thompson, SM; Troppoli, TA; Wulff, AB | 1 |
Jordan, I | 1 |
Bei, B; Wiley, JF | 1 |
Gründer, G; Mertens, L | 1 |
Blemings, A; Carhart-Harris, R; Nutt, DJ | 1 |
Bayat, M | 1 |
Bolstridge, M; Carhart-Harris, RL; Curran, HV; Demetriou, L; Kaelen, M; Leech, R; McGonigle, J; Murphy, K; Nutt, DJ; Pannekoek, JN; Roseman, L; Tanner, M; Wall, MB | 1 |
Johnson, MI; Whelan, A | 1 |
Flanagan, TW; Nichols, CD | 1 |
Ross, S | 1 |
Andreassen, OA; Kvam, TM; Stewart, LH | 1 |
Anderson, T; Dinh-Williams, LA; Farb, NAS; Hapke, E; Hui, K; Petranker, R; Rosenbaum, D; Weissman, CR | 1 |
Kuypers, KPC | 1 |
Christiansen, SL; Elfving, B; Højgaard, K; Jefsen, O; Müller, HK; Nutt, DJ; Wegener, G | 1 |
Bosch, OG; Kraehenmann, R; Pokorny, T; Preller, KH; Scheidegger, M; Seifritz, E; Vollenweider, FX | 1 |
Hawkes, N | 1 |
Cowen, P | 1 |
Hendrie, C; Pickles, A | 1 |
Cohen, AF; Dijkstra, FM; Jacobs, GE | 1 |
de Veen, BT; Homberg, JR; Schellekens, AF; Verheij, MM | 1 |
Barrett, FS; Bradstreet, MP; Griffiths, RR; Johnson, MW; Leoutsakos, JS | 1 |
Nutt, D | 1 |
Agin-Liebes, G; Babb, J; Belser, A; Bossis, A; Cohen, B; Corby, P; Guss, J; Kalliontzi, K; Malone, T; Mennenga, SE; Ross, S; Schmidt, BL; Su, Z | 1 |
Carducci, MA; Cosimano, MP; Griffiths, RR; Johnson, MW; Klinedinst, MA; Richards, BD; Richards, WA; Umbricht, A | 1 |
McCorvy, JD; Olsen, RH; Roth, BL | 1 |
Johnson, MW; Nichols, CD; Nichols, DE | 1 |
JAROS, O; KOVARIK, J; SERCL, M | 1 |
CANCRINI, L; D AGOSTINO, E; REDA, GC; VELLA, G | 1 |
Kochansky, GE; Lieff, J; Salzman, C; Shader, RI | 1 |
Rysánek, K | 1 |
26 review(s) available for psilocybin and Depression
Article | Year |
---|---|
Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Psilocybin | 2022 |
Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.
Topics: Anxiety; Depression; Hallucinogens; Humans; Psilocybin; Quality of Life | 2022 |
Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
Topics: Depression; Depressive Disorder, Major; Hallucinogens; Humans; Psilocybin; Psychotherapy | 2022 |
[The use of psilocybin for treatment-resistant depression].
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin; Randomized Controlled Trials as Topic | 2022 |
Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis.
Topics: Depression; Depressive Disorder, Major; Hallucinogens; Humans; Lysergic Acid Diethylamide; Psilocybin | 2023 |
Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Ketamine; Psilocybin | 2022 |
Topics: Depression; Humans; Psilocybin | 2023 |
Role of Psychedelics in Treatment-Resistant Depression.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Ketamine; Psilocybin | 2023 |
New Pharmacologic Approaches to the Treatment of Bipolar Depression.
Topics: Antidepressive Agents; Bipolar Disorder; Depression; Humans; Ketamine; Psilocybin; Randomized Controlled Trials as Topic; Treatment Outcome | 2023 |
Neurobiological Correlates of Psilocybin Response in Depression.
Topics: Antidepressive Agents; Brain; Depression; Humans; Psilocybin; Psychotherapy; Randomized Controlled Trials as Topic | 2023 |
Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis.
Topics: Depression; Escitalopram; Hallucinogens; Humans; Psilocybin; Sample Size; Symptom Flare Up | 2023 |
Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies.
Topics: Adult; Antidepressive Agents; Depression; Humans; Psilocybin; Psychotic Disorders; Randomized Controlled Trials as Topic | 2023 |
Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Hallucinogens; Humans; Psilocybin; Psychotherapy | 2023 |
Interaction of hallucinogenic rapid-acting antidepressants with mGlu2/3 receptor ligands as a window for more effective therapies.
Topics: Antidepressive Agents; Depression; Hallucinogens; Ketamine; Psilocybin; Receptors, Metabotropic Glutamate; Scopolamine | 2023 |
The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis.
Topics: Anxiety; Depression; Female; Humans; Male; Psilocybin; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Total Recall: Lateral Habenula and Psychedelics in the Study of Depression and Comorbid Brain Disorders.
Topics: Brain Diseases; Comorbidity; Depression; Depressive Disorder; Habenula; Hallucinogens; Humans; Psilocybin; Serotonergic Neurons | 2020 |
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
Topics: Affect; Banisteriopsis; Depression; Depressive Disorder, Major; Double-Blind Method; Hallucinogens; Healthy Volunteers; Humans; Lysergic Acid Diethylamide; Mood Disorders; Psilocybin; Randomized Controlled Trials as Topic; Serotonin Receptor Agonists; Treatment Outcome | 2021 |
Psychedelic Medicines in Major Depression: Progress and Future Challenges.
Topics: Depression; Depressive Disorder, Major; Hallucinogens; Humans; Psilocybin; Psychiatry | 2021 |
[Classic psychedelic drugs and their potential therapeutic effect].
Topics: Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Cluster Headache; Depression; Hallucinogens; Humans; Lysergic Acid Diethylamide; Obsessive-Compulsive Disorder; Psilocybin; Receptor, Serotonin, 5-HT2A; Substance-Related Disorders | 2017 |
Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role?
Topics: Anxiety; Chronic Pain; Depression; Humans; Lysergic Acid Diethylamide; Pain; Psilocybin; Serotonin Receptor Agonists; Treatment Outcome | 2018 |
Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress.
Topics: Anxiety; Depression; Hallucinogens; Humans; Lysergic Acid Diethylamide; Neoplasms; Psilocybin; Serotonin Antagonists; Stress, Psychological | 2018 |
Psychedelic drugs in the treatment of anxiety, depression and addiction.
Topics: Anxiety; Anxiety Disorders; Depression; Depressive Disorder; Hallucinogens; Humans; Lysergic Acid Diethylamide; Obsessive-Compulsive Disorder; Psilocybin; Substance-Related Disorders | 2018 |
Psilocybin for treating substance use disorders?
Topics: Depression; Emotions; Hallucinogens; Humans; Psilocybin; Substance-Related Disorders | 2017 |
Psychedelics as Medicines: An Emerging New Paradigm.
Topics: Anxiety; Brain; Clinical Trials as Topic; Depression; Dose-Response Relationship, Drug; Hallucinogens; Humans; Inflammation; Inflammation Mediators; Lysergic Acid Diethylamide; Mental Disorders; Mind-Body Therapies; Obsessive-Compulsive Disorder; Psilocybin; Psychotherapy; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Agonists; Severity of Illness Index; Substance-Related Disorders | 2017 |
[CLINICAL AND PSYCHOPATHOLOGICAL STUDY OF PSILOCYBIN].
Topics: Antisocial Personality Disorder; Asthenia; Blood Pressure; Consciousness; Depression; Depressive Disorder; Electroencephalography; Hallucinations; Hallucinogens; Hearing Disorders; Indoles; Mental Disorders; Mental Processes; Movement Disorders; Nausea; Pharmacology; Psilocybin; Psychopathology; Salivary Glands; Sweating; Toxicology; Vestibule, Labyrinth; Visual Perception | 1964 |
[Relation of monoamines to mental disorders].
Topics: Amines; Animals; Bipolar Disorder; Catecholamines; Central Nervous System; Depression; Dihydroxyphenylalanine; Dopamine; Epinephrine; Hallucinogens; Humans; Lysergic Acid Diethylamide; Mental Disorders; Methylation; Monoamine Oxidase Inhibitors; Phenethylamines; Psilocybin; Reserpine; Schizophrenia; Serotonin; Tryptamines | 1970 |
11 trial(s) available for psilocybin and Depression
Article | Year |
---|---|
Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study.
Topics: Adult; Anxiety; Cross-Over Studies; Depression; Dose-Response Relationship, Drug; Double-Blind Method; Emotions; Female; Hallucinogens; Humans; Male; Middle Aged; Psilocybin; Surveys and Questionnaires; Young Adult | 2022 |
[Psilocybin compared with escitalopram for depression].
Topics: Depression; Escitalopram; Hallucinogens; Humans; Psilocybin; Psychiatry | 2022 |
Increased global integration in the brain after psilocybin therapy for depression.
Topics: Antidepressive Agents; Brain; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Hallucinogens; Humans; Psilocybin | 2022 |
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Psilocybin; Treatment Outcome | 2022 |
Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.
Topics: Anxiety; Depression; Depressive Disorder, Major; Humans; Patient Reported Outcome Measures; Psilocybin; Quality of Life | 2023 |
Increased low-frequency brain responses to music after psilocybin therapy for depression.
Topics: Brain; Brain Mapping; Depression; Hallucinogens; Humans; Magnetic Resonance Imaging; Music; Psilocybin | 2023 |
Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Electroencephalography; Hallucinogens; Humans; Neuronal Plasticity; Psilocybin | 2023 |
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms.
Topics: Adult; Brain; Depression; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Psilocybin | 2017 |
Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.
Topics: Adult; Affect; Amygdala; Cross-Over Studies; Depression; Double-Blind Method; Female; Hallucinogens; Healthy Volunteers; Humans; Magnetic Resonance Imaging; Male; Psilocybin; Psychiatric Status Rating Scales; Young Adult | 2015 |
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
Topics: Adult; Aged; Anxiety; Cross-Over Studies; Depression; Double-Blind Method; Female; Hallucinogens; Humans; Male; Middle Aged; Neoplasms; Psilocybin; Psychotherapy; Quality of Life; Surveys and Questionnaires; Young Adult | 2016 |
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
Topics: Anxiety; Attitude; Cross-Over Studies; Depression; Double-Blind Method; Female; Follow-Up Studies; Hallucinogens; Humans; Male; Middle Aged; Neoplasms; Psilocybin; Quality of Life; Surveys and Questionnaires | 2016 |
53 other study(ies) available for psilocybin and Depression
Article | Year |
---|---|
Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers.
Topics: Adolescent; Adult; Anxiety; Cognition; Cross-Sectional Studies; Depression; Female; Hallucinogens; Humans; International Cooperation; Lysergic Acid Diethylamide; Male; Mental Health; Middle Aged; Motivation; Psilocybin; Surveys and Questionnaires; Young Adult | 2021 |
Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin | 2022 |
Psychiatry goes psychedelic.
Topics: Clinical Trials, Phase II as Topic; Depression; Escitalopram; Hallucinogens; Humans; Psilocybin; Psychiatry; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors | 2021 |
Psychedelic-assisted psychotherapy for the treatment of major depression: a synthesis of phenomenological explanations.
Topics: Depression; Depressive Disorder, Major; Hallucinogens; Humans; Psilocybin; Psychotherapy | 2022 |
Effects of the 5-HT
Topics: Animals; Depression; Fluorobenzenes; Hallucinogens; Lysergic Acid Diethylamide; Mescaline; Mice; Phenethylamines; Piperidines; Psilocybin; Rats; Receptor, Serotonin, 5-HT2A; Rodentia; Self Stimulation; Serotonin; Tryptamines | 2022 |
Psilocybin increases brain network integration in patients with depression.
Topics: Brain; Depression; Hallucinogens; Humans; Psilocybin | 2022 |
Rapid-Response Treatments for Depression and Requests for Physician-Assisted Death: An Ethical Analysis.
Topics: Depression; Ethical Analysis; Female; Humans; Ketamine; Physicians; Psilocybin; Suicide, Assisted | 2022 |
Psychedelic drugs take on depression.
Topics: Depression; Hallucinogens; Lysergic Acid Diethylamide; Psilocybin | 2022 |
The psychedelic escape from depression.
Topics: Depression; Hallucinogens; Humans; Psilocybin | 2022 |
Psilocybin in Treatment-Resistant Depression.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin | 2022 |
Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression.
Topics: Anhedonia; Depression; Emotions; Hallucinogens; Humans; Magnetic Resonance Imaging; Music; Psilocybin | 2023 |
A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability.
Topics: Depression; Depressive Disorder, Major; Hallucinogens; Humans; Mania; Psilocybin; Psychotic Disorders | 2022 |
On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin; Suicide | 2023 |
Psilocybin for Treatment-Resistant Depression.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin | 2023 |
Psilocybin for Treatment-Resistant Depression.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin | 2023 |
Psilocybin for Treatment-Resistant Depression.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin | 2023 |
Psilocybin for Treatment-Resistant Depression. Reply.
Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin | 2023 |
Psilocybin therapy for depression. A good trip?
Topics: Depression; Humans; Psilocybin | 2023 |
Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder.
Topics: Depression; Depressive Disorder, Major; Humans; Neoplasms; Patients; Psilocybin | 2023 |
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression.
Topics: Clinical Trials as Topic; Depression; Depressive Disorder, Major; Escitalopram; Humans; Psilocybin; Psychiatric Status Rating Scales; Reproducibility of Results | 2023 |
Letter to the editor on "Increased low-frequency brain responses to music after psilocybin therapy for depression".
Topics: Brain; Depression; Hallucinogens; Humans; Music; Psilocybin | 2023 |
Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.
Topics: Australia; Depression; Drug Approval; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Stress Disorders, Post-Traumatic; Time Factors | 2023 |
Australia's approval of MDMA and psilocybin for PTSD and depression is premature, say critics.
Topics: Australia; Depression; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Stress Disorders, Post-Traumatic | 2023 |
Psilocybin-assisted psychotherapy for cancer-related anxiety and depression.
Topics: Anxiety; Depression; Humans; Neoplasms; Psilocybin; Psychotherapy | 2023 |
Psilocybin-assisted psychotherapy for treatment-resistant depression: Which psychotherapy?
Topics: Depression; Emotions; Hallucinogens; Humans; Psilocybin; Psychotherapy | 2023 |
Topics: Depression; Humans; Psilocybin | 2023 |
Psychedelic treatments are speeding towards approval - but no one knows how they work.
Topics: Depression; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychological Trauma; Uncertainty | 2023 |
Psilocybin therapy to reduce depression following a terminal diagnosis.
Topics: Anxiety; Depression; Humans; Psilocybin | 2023 |
UNCOVERING THE UNTAPPED POTENTIAL OF PSILOCYBIN THERAPY IN ALLEVIATING CANCER-RELATED DEPRESSION: AN URGENT CALL TO RE-EVALUATE TREATMENT STRATEGIES.
Topics: Depression; Hallucinogens; Humans; Neoplasms; Psilocybin | 2023 |
The Psilocybin-Telomere Hypothesis: An empirically falsifiable prediction concerning the beneficial neuropsychopharmacological effects of psilocybin on genetic aging.
Topics: Aging; Aging, Premature; Animals; Anxiety; Brain-Derived Neurotrophic Factor; Consciousness; Depression; Disease Models, Animal; DNA Methylation; Endocrine System; Humans; Models, Genetic; Models, Psychological; Neurotransmitter Agents; Oxidative Stress; Personality; Psilocybin; Psychotropic Drugs; Research Design; Serotonin Plasma Membrane Transport Proteins; Stress, Psychological; Telomere Shortening | 2020 |
Microdosing psychedelics: Motivations, subjective effects and harm reduction.
Topics: Adult; Anxiety; Depression; Dose-Response Relationship, Drug; Female; Hallucinogens; Harm Reduction; Humans; Lysergic Acid Diethylamide; Male; Mental Health; Middle Aged; Motivation; Psilocybin; Substance-Related Disorders; Surveys and Questionnaires; Young Adult | 2020 |
Psilocybin Can Diminish Depression.
Topics: Anxiety; Depression; Hallucinogens; Humans; Psilocybin | 2020 |
Psilocybin-Assisted Supportive Psychotherapy in the Treatment of Major Depression-Quo Vadis?
Topics: Depression; Depressive Disorder, Major; Humans; Psilocybin; Psychotherapy | 2021 |
How ecstasy and psilocybin are shaking up psychiatry.
Topics: Animals; Certification; Clinical Trials as Topic; Depression; Depressive Disorder, Treatment-Resistant; Drug Prescriptions; Efficiency; Humans; Lysergic Acid Diethylamide; N-Methyl-3,4-methylenedioxyamphetamine; N,N-Dimethyltryptamine; Neuronal Plasticity; Niacin; Psilocybin; Psychiatry; Psychotherapy; Rumination, Cognitive; Selective Serotonin Reuptake Inhibitors; Serotonin; Stress Disorders, Post-Traumatic | 2021 |
Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice.
Topics: Animals; Depression; Drug Evaluation, Preclinical; Hallucinogens; Hippocampus; Ketanserin; Male; Mice, Inbred C57BL; Psilocybin; Receptors, Serotonin, 5-HT2; Serotonin 5-HT2 Receptor Agonists; Stress, Psychological | 2021 |
Psilocybin for Depression.
Topics: Anxiety; Depression; Humans; Psilocybin | 2021 |
Psilocybin for Depression.
Topics: Anxiety; Depression; Humans; Psilocybin | 2021 |
Psilocybin for Depression.
Topics: Anxiety; Depression; Humans; Psilocybin | 2021 |
Psilocybin for Depression.
Topics: Anxiety; Depression; Humans; Psilocybin | 2021 |
Psilocybin for Depression. Reply.
Topics: Anxiety; Depression; Humans; Psilocybin | 2021 |
Psychedelics as anti-inflammatory agents.
Topics: Amphetamines; Animals; Anti-Inflammatory Agents; Anxiety; Behavior, Animal; Depression; Hallucinogens; Humans; Obsessive-Compulsive Disorder; Psilocybin; Receptor, Serotonin, 5-HT2A | 2018 |
Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.
Topics: Adult; Anxiety; Creativity; Depression; Dose-Response Relationship, Drug; Emotions; Female; Hallucinogens; Humans; Lysergic Acid Diethylamide; Male; Mental Health; Perception; Personality; Psilocybin; Surveys and Questionnaires | 2019 |
Psychedelic medicine: The biology underlying the persisting psychedelic effects.
Topics: Animals; Banisteriopsis; Cognition; Consciousness; Depression; Diet; Hallucinogens; Humans; Life Style; Lysergic Acid Diethylamide; Microbiota; Models, Biological; Psilocybin; Sleep | 2019 |
Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Male; Motor Activity; Psilocybin; Rats | 2019 |
Sixty seconds on . . . psilocybin.
Topics: Depression; Dose-Response Relationship, Drug; Hallucinogens; Humans; London; Psilocybin | 2016 |
Altered states: psilocybin for treatment-resistant depression.
Topics: Depression; Depressive Disorder, Treatment-Resistant; Feasibility Studies; Hallucinogens; Humans; Psilocybin | 2016 |
Psilocybin: panacea or placebo?
Topics: Depression; Depressive Disorder, Treatment-Resistant; Feasibility Studies; Hallucinogens; Humans; Psilocybin | 2016 |
Question-based Drug Development for psilocybin.
Topics: Depression; Drug Development; Feasibility Studies; Hallucinogens; Psilocybin | 2016 |
The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.
Topics: Adult; Affect; Agaricales; Anxiety; Depression; Emotions; Female; Hallucinogens; Humans; Male; Psilocybin; Surveys and Questionnaires | 2016 |
Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future.
Topics: Anxiety; Depression; Hallucinogens; Humans; Neoplasms; Psilocybin | 2016 |
Psilocybin for depression and anxiety associated with life-threatening illnesses.
Topics: Anxiety; Depression; Depressive Disorder; Hallucinogens; Humans; Psilocybin | 2016 |
[Clinical experiences with psilocybin (CY 39 Sandoz)].
Topics: Depression; Depressive Disorder; Indoles; Neurotic Disorders; Psilocybin | 1961 |
The psychology of hallucinogenic drug discontinuers.
Topics: Adult; Anxiety; Depression; Female; Gambling; Hallucinogens; Humans; Lysergic Acid Diethylamide; Male; Mental Disorders; Mescaline; MMPI; Personality; Psilocybin; Psychological Tests; Substance-Related Disorders | 1972 |